ConvaTec Group PLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ConvaTec Group PLC
The French firm will use the funds to establish proof-of-concept for two gene therapy programs in a rare eye condition as it strives to become a world leader in ophthalmic genomic medicine, its CEO tells Scrip.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
ConvaTec will pay $125m upfront for Memphis-based Triad, plus up to $50m in short-term milestone payments and up to $275m more contingent on Triad’s financial performance over the next two years.
Robot’s surgeon or surgeon’s robot? Swiss innovator Distalmotion is pressing ahead with the latter approach having added new directors, and new funding and commercial scale-up resources to further the global vision for its laparoscopic-robotic surgery tool with a difference.
- Drug Delivery
- Consumables, Central Supplies
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Rehabilitation Equipment and Devices
- Surgical Equipment & Devices
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Hospitak, Inc.
- Maersk Medical
- Unomedical a/s
- Woodbury Holdings
- ConvaTec, Inc.